ProMed Pharma to Showcase Long-Acting Drug Delivery Capabilities at CPHI Milan and PODD Boston

Company to Highlight Polymer-Based Controlled-Release Expertise for Implants, Injectables, and Combination Products



ProMed Pharma uses precision molding and extrusion to manufacture drug-loaded polymer implants and combination-product components for long-acting therapies.

PLYMOUTH, MN, UNITED STATES, September 23, 2026 / EINPresswire.com/ -- ProMed Pharma, a leading contract development and manufacturing organization (CDMO) specializing in long-acting injectable and implantable drug delivery systems, today announced that it will attend two major industry events in October: CPHI Milan, taking place October 6–8, 2026, at Fiera Milano in Milan, Italy, and PODD: Partnership Opportunities in Drug Delivery, taking place October 29–30, 2026, at the Sheraton Boston Hotel in Boston, Massachusetts.
At both events, ProMed's business development and technical leaders will meet with pharmaceutical and biotechnology companies seeking a development and manufacturing partner for complex, polymer-based extended-release dosage forms, including drug-eluting implants, long-acting injectables, and drug-device combination products.

ProMed will highlight its core technical capabilities, including hot melt extrusion, injection molding of drug-loaded polymers, microencapsulation, and potent API handling, working across a broad range of polymeric excipients including silicones, thermoplastics, and biodegradables. The company supports partners across the full product lifecycle, from early drug product feasibility studies through tech transfer, scale-up, clinical supply, and commercial cGMP manufacturing.

"CPHI and PODD bring together exactly the companies we want to be talking with: innovators working on long-acting therapies and developers pursuing novel dosage forms," said James Arps, PhD, Director of Business Development at ProMed Pharma. "Interest in polymer-based

> CPHI and PODD bring together exactly the companies we want to be talking with: innovators working on long-acting therapies”
>
> *James Arps, PhD, ProMed Pharma*

controlled release continues to grow, and we're looking forward to discussing how our formulation and manufacturing expertise can help partners move their programs forward."

"Long-acting delivery is one of the most active areas in the industry, and many programs need a partner who understands both the polymer science and the manufacturing realities," added Dr. Arps. "We support partners from early feasibility through commercial supply, and these meetings are a great chance to explore where we can help."

Attendees interested in scheduling a meeting with ProMed Pharma at either event can contact the company at info@promedpharmallc.com or visit www.promedpharmallc.com.

Jim Arps
ProMed Pharma
+1 7633313800
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/944617322

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.